News 17 Nov 2022 Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option admin
News 15 Nov 2022 Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering admin
News 10 Nov 2022 Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes & Reduce Costs admin
News 03 Nov 2022 Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure admin
News 31 Oct 2022 Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022 admin
News 05 Oct 2022 Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting admin
News 04 Oct 2022 Daxor Corporation to Exhibit & Present at the Medaxiom Cardiovascular Transforum Conference Fall’22 to Advance Awareness & Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®) admin
News 04 Oct 2022 Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting admin
News 03 Oct 2022 New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55% admin
